Trial record 3 of 126 for:
"COL4A1-related brain small-vessel disease" OR "Cerebral Hemorrhage"
Diagnostic Utility of MRI in Intracerebral Hemorrhage
This study is currently recruiting participants.
Verified June 2012 by Stanford University
Information provided by (Responsible Party):
First received: August 9, 2006
Last updated: June 12, 2012
Last verified: June 2012
The overall aim of this project is to prospectively determine whether MRI can improve the conventional neuroradiological evaluation (CT with or without cerebral angiography) of patients with a spontaneous ICH or IVH. The study design will also allow us to identify the added benefit of specific MR sequences and repeat MRI in the chronic stage, thereby allowing us to prospectively determine their value in a consecutive series of patients. This information should have a major impact on the management of these patients by providing data on the diagnostic yield of routine MRI in patients presenting with a wide variety of causes for ICH or IVH. These data will help guide the diagnostic evaluation and the management of brain hemorrhage patients in the future.
||Observational Model: Cohort
Time Perspective: Prospective
||Diagnostic Utility of MRI in Intracerebral Hemorrhage
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||April 2013 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
A total of 180 ICH or IVH patients will be studied. All patients will be inpatients admitted to the Stanford Stroke Center, a multidisciplinary referral center for the treatment of acute stroke. Consecutive patients will be enrolled provided they meet the inclusion and exclusion criteria and that they or a legally authorized representative give informed consent.
A. Men and non-pregnant women, at least 18 years of age.
B. Patients with an ICH or IVH admitted to Stanford University Medical center within 48 hours of symptom onset.
C. Ability to undergo MRI.
A. Patients with a known (preexisting) source for ICH, for example a known untreated arterio-venous malformation.
B. Patients receiving investigational drug therapies or procedures prior to MRI scanning.
C. Glasgow coma scale (GCS) score < 6 in the absence of sedating medications.
D. Informed consent cannot be obtained either directly from the patient or from a legally authorized representative.
E. Severe coexisting or terminal systemic disease that limits life expectancy or that may interfere with the conduct of the study
Please refer to this study by its ClinicalTrials.gov identifier: NCT00363662
|Stanford University School of Medicine
|Stanford, California, United States, 94305 |
|Contact: Stephanie M Kemp, BS 650-723-4481 email@example.com |
|Contact: Eyngorn, MD (650) 498-7333 firstname.lastname@example.org |
|Principal Investigator: Christine Wijman |
|Sub-Investigator: Gregory W Albers |
|Sub-Investigator: Michael E. Moseley |
|Sub-Investigator: Maarten G Lansberg MD, PhD |
|Sub-Investigator: Anna K. Finley Caulfield |
|Sub-Investigator: Neil Schwartz |
|Sub-Investigator: Dr Marion S Buckwalter |
|Sub-Investigator: Dr. chitra venkat |
|Sub-Investigator: Waimei A Tai, MD |
|Sub-Investigator: Jean Marc Olivot, MD |
No publications provided
History of Changes
|Other Study ID Numbers:
||2 R01 NS034866-08A1
|Study First Received:
||August 9, 2006
||June 12, 2012
||United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 18, 2013
Central Nervous System Diseases
Nervous System Diseases